BMS-986165

Showing 1 posts of 1 posts found.

BMS’ investigational psoriasis drug hits primary endpoint in skin clearance at Phase 2

September 12, 2018
Research and Development BMS, BMS-986165, Bristol-Myers Squibb, pharma, psoriasis

Bristol-Myers Squibb has unveiled new Phase 2 data for its investigational oral, selective tyrosine kinase 2 (TYK2) inhibitor, known as …

Latest content